JP2004520365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004520365A5 JP2004520365A5 JP2002557927A JP2002557927A JP2004520365A5 JP 2004520365 A5 JP2004520365 A5 JP 2004520365A5 JP 2002557927 A JP2002557927 A JP 2002557927A JP 2002557927 A JP2002557927 A JP 2002557927A JP 2004520365 A5 JP2004520365 A5 JP 2004520365A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- cycloalkyl
- group
- following
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0101204.6A GB0101204D0 (en) | 2001-01-17 | 2001-01-17 | Biologically active compounds |
| US27550601P | 2001-03-13 | 2001-03-13 | |
| PCT/GB2002/000194 WO2002057246A2 (en) | 2001-01-17 | 2002-01-17 | Inhibitors of cruzipain and other cysteine proteases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004520365A JP2004520365A (ja) | 2004-07-08 |
| JP2004520365A5 true JP2004520365A5 (https=) | 2005-12-22 |
Family
ID=26245574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002557927A Pending JP2004520365A (ja) | 2001-01-17 | 2002-01-17 | クルジパインおよび他のシステインプロテアーゼの阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6958358B2 (https=) |
| EP (1) | EP1358176A2 (https=) |
| JP (1) | JP2004520365A (https=) |
| CA (1) | CA2434068A1 (https=) |
| IL (1) | IL156776A0 (https=) |
| NZ (1) | NZ526912A (https=) |
| WO (1) | WO2002057246A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004523506A (ja) * | 2000-12-22 | 2004-08-05 | アクシス・ファーマシューティカルズ・インコーポレイテッド | カテプシン阻害剤としての新規な化合物と組成物 |
| US20040147503A1 (en) * | 2002-06-04 | 2004-07-29 | Sheila Zipfeil | Novel compounds and compositions as cathepsin inhibitors |
| CA2569887A1 (en) | 2004-06-09 | 2005-12-22 | Glaxo Group Limited | Pyrrolopyridine derivatives |
| AU2006316321A1 (en) * | 2005-11-22 | 2007-05-31 | Merck & Co., Inc. | Indole orexin receptor antagonists |
| GB0614042D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
| EP2719700A1 (en) | 2008-01-09 | 2014-04-16 | Amura Therapeutics Limited | Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases |
| US20110046044A1 (en) * | 2009-08-24 | 2011-02-24 | Samsung Electronics Co., Ltd. | Use of a cysteine protease of Plasmodium vivax |
| US9409880B2 (en) | 2011-01-20 | 2016-08-09 | The Regents Of The University Of Colorado, A Body Corporate | Modulators of TLR3/dsRNA complex and uses thereof |
| WO2026037930A1 (en) * | 2024-08-16 | 2026-02-19 | Anavo Therapeutics Bv | Amide derivatives as wip1 inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3652574A (en) | 1970-04-01 | 1972-03-28 | Abbott Lab | Certain 1 2 3 4 - tetrahydro-5h-pyrido (4 3-b)indoles and the corresponding 1 2 3 4-tetrahydro-9h-pyrido(3 4-b)indoles and derivatives thereof |
| DZ2285A1 (fr) | 1996-08-08 | 2002-12-25 | Smithkline Beecham Corp | Inhibiteurs de protéase de la cystéine. |
| EP0923535A4 (en) | 1996-08-28 | 2001-01-10 | Smithkline Beecham Corp | CYSTEINE PROTEASE INHIBITORS |
| EA002100B1 (ru) | 1996-12-23 | 2001-12-24 | Элан Фармасьютикалз, Инк. | ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ |
| AR013079A1 (es) * | 1997-05-06 | 2000-12-13 | Smithkline Beecham Corp | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios |
| MA26618A1 (fr) | 1998-04-09 | 2004-12-20 | Smithkline Beecham Corp | Composes et compositions pharmaceutiques pour le traitement du paludisme |
| CO5150165A1 (es) * | 1998-11-13 | 2002-04-29 | Smithkline Beecham Plc | Inhibidores de proteasa: tipo catepsina k |
| GB9911417D0 (en) * | 1999-05-18 | 1999-07-14 | Peptide Therapeutics Ltd | Furanone derivatives as inhibitors of cathepsin s |
| JP2004513942A (ja) | 2000-11-17 | 2004-05-13 | メディヴァー ユーケイ リミテッド | システインプロテアーゼインヒビター |
| JP2004523506A (ja) | 2000-12-22 | 2004-08-05 | アクシス・ファーマシューティカルズ・インコーポレイテッド | カテプシン阻害剤としての新規な化合物と組成物 |
-
2002
- 2002-01-17 JP JP2002557927A patent/JP2004520365A/ja active Pending
- 2002-01-17 WO PCT/GB2002/000194 patent/WO2002057246A2/en not_active Ceased
- 2002-01-17 EP EP02715508A patent/EP1358176A2/en not_active Withdrawn
- 2002-01-17 US US10/466,385 patent/US6958358B2/en not_active Expired - Fee Related
- 2002-01-17 NZ NZ526912A patent/NZ526912A/en unknown
- 2002-01-17 CA CA002434068A patent/CA2434068A1/en not_active Abandoned
- 2002-01-17 IL IL15677602A patent/IL156776A0/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004518674A5 (https=) | ||
| Maher et al. | Oxidative and electrophilic stress induces multidrug resistance–associated protein transporters via the nuclear factor‐E2–related factor‐2 transcriptional pathway | |
| US20250276066A1 (en) | Methods, compositions and compounds for treating age-related diseases and conditions | |
| JP4414229B2 (ja) | 難聴を治療する方法 | |
| AR036032A1 (es) | Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif | |
| RU2003125270A (ru) | Ингибиторы крузипаина и других цистеинпротеаз | |
| JP2013530964A5 (https=) | ||
| JP2021510376A5 (https=) | ||
| JP2009520038A5 (https=) | ||
| KR930002372A (ko) | 약리학적으로 활성인 히드라진 유도체 및 이의 제조방법 | |
| KR102452370B1 (ko) | 신경교종을 포함하는 암을 치료하기 위해 에플로르니틴 및 이의 유도체 및 동족체를 사용하기 위한 조성물 및 방법 | |
| TR200200415T2 (tr) | İkame edilmiş fenilusikloheksil bileşimlerinden elde edilmiş yeni esterler. | |
| EP1197210B1 (en) | Agents inhibiting chronic rejection reactions after organ transplantation | |
| Deininger | Resistance to imatinib: mechanisms and management | |
| JP2004536858A5 (https=) | ||
| JP2010501479A5 (https=) | ||
| JP2003530432A5 (https=) | ||
| JP2004520365A5 (https=) | ||
| US9649313B2 (en) | Use of ITK inhibitors for the treatment of cancer | |
| JP2009541387A5 (https=) | ||
| WO2018083138A1 (en) | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents | |
| EP0671390A3 (en) | Antithrombotic agents | |
| US20140213583A1 (en) | PI3K Inhibitor for Use in the Treatment of Bone Cancer or for Preventing Metastatic Dissemination Primary Cancer Cells into the Bone | |
| KR910004568A (ko) | 치환 n-(퀴놀린-2-일-메톡시)벤질-술포닐우레아 | |
| CN107296807A (zh) | Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用 |